Veru(VERU)

Focus: Veru is a public biotechnology company focused on small molecule therapeutics targeting prostate cancer and other oncology indications. The company operates at mid-cap scale with a diversified pipeline spanning multiple cancer types and indications.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Veru

AI assessmentNot Hiring

No open roles listed right now. Follow Veru to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$16M

Pipeline & Clinical Trials

VERU-100

Advanced Prostate Adenocarcinoma

Phase 1/2

Clinical Trials (1)

NCT04843319To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer

Phase 1/2

Help build intelligence for Veru

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline with multiple Phase 3 programs (VERU-111 in mCRPC, enobosarm combinations in breast cancer) offering near-term regulatory catalysts
Diversified therapeutic approach across prostate cancer, breast cancer, and emerging viral indications demonstrates scientific breadth
Public company status with established infrastructure and capital access for continued development

Watch Out For

Severe cash constraints with only $25M cash (FY2025) against $37.8M net losses and declining R&D spend ($51M to $13M YoY), raising runway concerns
Zero active job openings and minimal published research output suggest limited hiring and internal scientific productivity
Negative profitability with $93M net loss in FY2024 and collapsing revenue ($16M FY2024) indicates existential financial stress

Generated by Claude from Veru's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

VERU-111

Metastatic Castration Resistant Prostate Cancer

Phase 1/2

Clinical Trials (1)

NCT03752099To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Phase 1/2

Enobosarm

Obesity & Overweight

Phase 2

Clinical Trials (1)

NCT07446998Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

Phase 2

Enobosarm

Muscle Loss

Phase 2

Clinical Trials (1)

NCT06282458Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

Phase 2

Veru-944

Prostate Cancer Metastatic

Phase 2

Clinical Trials (1)

NCT03646162Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer